Insys Therapeutics ran into some bad news and trouble with the FDA. They beat on earnings but guidance was disappointing.
NEW BULLISH Plays
No New Bullish Plays
NEW BEARISH Plays
INSY - Insys Therapeutics - Company Profile
Insys is a specialty pharmaceutical company that develops and commercializes supportive care products. Their main drug (Subsys) is a sublingual fentanyl spray for cancer pain in opioid-tolerant patients.
They warned before earnings that Q1 sales of Subsys would only be in the range of $61-$62 million after Q4 sales were in the $91 million range, up +38%. In the year ago quarter Subsys sales were $70.5 million.
The problem is what the FDA said was improper off-label marketing that expanded the use of the drug last year. With that practice halted analysts believe the drug's best days are over.
Compounding the revenue problem was a decision by the FDA to move an approval date for Syndros from April 1st to July 1st. Syndros is a reformulation of the marijuana based drug marinol. Insys believes this could be a big seller in the hundreds of millions of dollars.
While that may be good for Insys in the future the trader community is leaving the stock until we get closer to the approval date.
Insys reported earnings of 11 cents that beat estimates for 8 cents. Revenue from Subsys was $62 million. Shares have been declining since the earnings report because of the revenue warning.
Earnings July 28th.
With an INSY trade at $13.60
Short INSY shares, initial stop loss $14.60